Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zorpocabtagene autoleucel (Miltenyi Biomedicine GmbH)
- Development stage
- Unknown
- Lead developer
- Miltenyi Biomedicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Zorpocabtagene autoleucel (Zorpo-cel, MB-CART19.1) is an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy developed by Miltenyi Biomedicine. It is manufactured using a fully automated, closed, and GMP-compliant CliniMACS Prodigy system. The CAR construct is a second-generation CD19-directed CAR containing an FMC63-based single-chain variable fragment (scFv) targeting domain, a CD8 hinge region, a TNFRSF19 transmembrane domain, a 4-1BB (CD137) costimulatory domain, and a CD3-zeta activation domain. It is being developed for the treatment of B-cell malignancies (such as diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and non-Hodgkin lymphoma) and various B-cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome (APLAS).
- Brand names
- Zorpo-cel
- Other names
- MB-19.1 CAR T-cellsMB19.1 CAR T-cellsMB 19.1 CAR T-cellsMB-19.1-CD19-CARTMB19.1-CD19-CARTMB 19.1-CD19-CARTMB-CART-19MB-CART19MB-CART 19anti-CD-MB-19.1-CART-cellsanti-CD-MB19.1-CART-cellsanti-CD-MB 19.1-CART-cellsanti-CD19.1-CAR-T cellsanti-CD-19.1-CAR-T cellsanti-CD 19.1-CAR-T cells
Beyond the preview
Go deeper on zorpocabtagene autoleucel (Miltenyi Biomedicine GmbH).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zorpocabtagene autoleucel (Miltenyi Biomedicine GmbH).